Search clinical trials for: sorafenib and cisplatin

Total 269901 results

British Columbia Cancer Agency

Withdrawn

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Canada
Asan Medical Center
Bayer

Completed

Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE

Effects of Chemotherapy | Malignant Neoplasm of Stomach

Korea, Republic of
Asan Medical Center

Completed

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP

Advanced Gastric Cancer

Korea, Republic of
Lahey Clinic

Withdrawn

Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Kindai University

Completed

Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy (SILIUS)

Hepatocellular Carcinoma

Japan
Shantou University Medical College

Unknown

Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

Pleural Effusion, Malignant

China
Yabao Pharmaceutical Group

Completed

Bioequivalence Study of Sorafenib Tablet and Nexavar

Fasting

Canada
UNICANCER

Completed

Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors (PACIFIK)

Metastatic Cancer | Solid Tumors

France
Gruppo Italiano per lo studio dei Carcinomi dell...
Mario Negri Institute for Pharmacological Research

Unknown

Metastatic Advanced Pancreas Sorafenib (MAPS)

Locally Advanced Pancreatic Cancer

Italy
Trans Tasman Radiation Oncology Group
National Health and Medical Research Council, Australia

Completed

Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.

Transitional Cell Carcinoma of Urinary Bladder

Australia, New Zealand
Afshin Dowlati, MD
National Cancer Institute (NCI)

Terminated

Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tigermed Consulting Co., Ltd

Completed

Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

HCC

China
University Health Network, Toronto
Bayer

Completed

A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

Cancer of the Cervix

Canada
Julie E. Bauman, MD, MPH
Novartis

Withdrawn

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Oropharyngeal Neoplasms | Oropharyngeal Cancer | Squamous Cell Carcinoma | Carcinoma, Squamous
Sun Yat-sen University

Completed

Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Neoplasms

China
Duke University
Bayer

Terminated

Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma

Melanoma
University of Miami

Completed

Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Liver Cancer

United States
Wuhan Union Hospital, China

Unknown

Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion

Malignant Pleural Effusion

China
Memorial Sloan Kettering Cancer Center
Bayer

Terminated

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer | URINARY BLADDER

United States
Washington University School of Medicine

Terminated

Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

Breast Cancer

United States
Allarity Therapeutics

Completed

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (LiPlaCis)

Phase 1: Advanced or Refractory Solid Tumours | Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer

Denmark
University Health Network, Toronto

Completed

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Canada
Bayer

Completed

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) (NEXUS)

Carcinoma, Non-Small-Cell Lung

Belgium, Spain, France, Switzerland, Greece, Italy, Hungary, Canada, Netherlands, United Kingdom, Austria, China, Israel, Mexico, Germany, Brazil, Finland, Cyprus
Bayer
Amgen

Completed

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Carcinoma

United States
The Netherlands Cancer Institute
Karolinska Institutet; UMC Utrecht; Maastricht Radiation Oncology; The Christie... and other collaborators

Active, not recruiting

Adaptive Radiation Treatment for Head and Neck Cancer (ARTFORCE)

Head and Neck Cancer

Spain, Netherlands, Sweden, France, United Kingdom
Radboud University Medical Center

Completed

Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients

Melanoma

Netherlands
Ohio State University Comprehensive Cancer Center
Bayer

Terminated

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Technical University of Munich

Completed

Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)

Renal Cell Carcinoma

Austria, Germany, Netherlands
Ottawa Hospital Research Institute
Bayer

Completed

Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Canada
National Cancer Institute (NCI)

Completed

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Metastatic Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction | Advanced Unresectable Gastric Cancer

United States
Masonic Cancer Center, University of Minnesota

Completed

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Prostate Cancer | Mesothelioma

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

Bladder Cancer

Italy
Cancer Institute and Hospital, Chinese Academy...

Completed

Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma (SIRAHCC)

Hepatocellular Carcinoma, Radiotherapy, Sorafenib

China
Curis, Inc.

Completed

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Head and Neck Cancer

United States
Georgetown University

Terminated

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Head and Neck Squamous Cell Cancer

United States
Yiviva Inc.

Recruiting

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

United States, Taiwan, China, Hong Kong
National Cancer Institute (NCI)

Completed

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States
New Mexico Cancer Care Alliance

Terminated

Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States
The Netherlands Cancer Institute

Active, not recruiting

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Neuroendocrine Carcinomas

Netherlands
China Medical University Hospital

Unknown

Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Taiwan
Accelerated Community Oncology Research Network
Bayer

Terminated

Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
China Medical University Hospital

Unknown

Combined Radiotherapy and Sorafenib in Patients With Hepatoma

Hepatocellular Carcinoma

Taiwan
ARCAGY/ GINECO GROUP

Completed

CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto

Cervix Cancer

France
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Centre, Singapore

Terminated

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Singapore
Bayer

Completed

Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients (HATT)

Hepatocellular Carcinoma

Taiwan
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

Gastrointestinal Stromal Tumor

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Recurrent Thyroid Gland Medullary Carcinoma | Hereditary Thyroid Gland Medullary Carcinoma | Locally Advanced Thyroid Gland Medullary Carcinoma | Sporadic Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary... and other conditions

United States
Indiana University School of Medicine
Bayer

Completed

Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Promyelocytic, Acute

United States

Search clinical trials for: sorafenib and cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations